Eli Lilly and Company $LLY Shares Bought by Riverbend Wealth Management LLC

Key Points

• Riverbend Wealth Management LLC increased its holdings in Eli Lilly and Company by 49.7% during the second quarter, now owning approximately 1.0% of its investment portfolio in the company.
• Insider purchases included Director Jamere Jackson, who bought 200 shares for $127,912, and Director Gabrielle Sulzberger, who acquired 117 shares for $75,018, increasing their ownership percentages.
• Eli Lilly reported strong quarterly earnings, with an EPS of $6.31, surpassing the analysts' expectations of $5.59, coupled with a 37.6% increase in revenue year-over-year.

Riverbend Wealth Management LLC raised its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 49.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,660 shares of the company's stock after purchasing an additional 551 shares during the quarter. Eli Lilly and Company accounts for approximately 1.0% of Riverbend Wealth Management LLC's investment portfolio, making the stock its 29th biggest holding. Riverbend Wealth Management LLC's holdings in Eli Lilly and Company were worth $1,294,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the stock. WestEnd Advisors LLC raised its position in Eli Lilly and Company by 210.0% during the first quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock valued at $26,000 after acquiring an additional 21 shares in the last quarter. Wealth Preservation Advisors LLC purchased a new stake in Eli Lilly and Company in the 1st quarter worth approximately $27,000. Citizens National Bank Trust Department grew its stake in shares of Eli Lilly and Company by 180.0% during the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock worth $35,000 after purchasing an additional 27 shares during the period. Financial Gravity Asset Management Inc. acquired a new stake in shares of Eli Lilly and Company during the 1st quarter worth approximately $40,000. Finally, TD Capital Management LLC increased its holdings in shares of Eli Lilly and Company by 129.2% during the 1st quarter. TD Capital Management LLC now owns 55 shares of the company's stock valued at $46,000 after purchasing an additional 31 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, Director Jamere Jackson bought 200 shares of the company's stock in a transaction dated Friday, August 8th. The stock was acquired at an average price of $639.56 per share, with a total value of $127,912.00. Following the completion of the acquisition, the director directly owned 9,402 shares of the company's stock, valued at $6,013,143.12. This represents a 2.17% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Gabrielle Sulzberger bought 117 shares of Eli Lilly and Company stock in a transaction dated Tuesday, August 12th. The stock was acquired at an average price of $641.18 per share, with a total value of $75,018.06. Following the completion of the transaction, the director directly owned 2,703 shares of the company's stock, valued at approximately $1,733,109.54. The trade was a 4.52% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders acquired 4,514 shares of company stock valued at $2,894,841. Insiders own 0.13% of the company's stock.

Analysts Set New Price Targets

A number of analysts recently issued reports on the stock. DZ Bank raised shares of Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a report on Thursday, August 14th. Erste Group Bank upgraded shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a research report on Tuesday. JPMorgan Chase & Co. lowered their target price on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an "overweight" rating on the stock in a research note on Tuesday, September 16th. Guggenheim restated a "buy" rating and issued a $948.00 price target on shares of Eli Lilly and Company in a research note on Thursday. Finally, Deutsche Bank Aktiengesellschaft reduced their price target on Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating for the company in a report on Monday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the company's stock. According to data from MarketBeat, Eli Lilly and Company has an average rating of "Moderate Buy" and an average price target of $939.12.

Eli Lilly and Company Stock Down 1.0%

LLY stock opened at $818.45 on Friday. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $935.63. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. The firm has a 50-day simple moving average of $749.52 and a 200-day simple moving average of $766.23. The stock has a market capitalization of $774.63 billion, a P/E ratio of 53.49, a P/E/G ratio of 1.18 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same period last year, the company posted $3.92 EPS. Eli Lilly and Company's quarterly revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Equities analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.